Literature DB >> 12938926

Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction.

John Marshall1, Peter Kupchak, Weimin Zhu, Jason Yantha, Tammy Vrees, Shirley Furesz, Kellie Jacks, Chris Smith, Inga Kireeva, Rulin Zhang, Miyoko Takahashi, Eric Stanton, George Jackowski.   

Abstract

The MALDI-TOF spectra of peptides from the sera of normal and myocardial infarction patients produced patterns that provided an accurate diagnostic of MI. In myocardial infarction, the spectral pattern originated from the cleavage of complement C3 alpha chain to release the C3f peptide and cleavage of fibrinogen to release peptide A. The fibrinogen peptide A and complement C3f peptide were in turn progressively truncated by aminopeptidases to produce two families of fragments that formed the characteristic spectral pattern of MI. Time course and inhibitor studies demonstrated that the peptide patterns in the serum reflect the balance of disease-specific-protease and aminopeptidase activity ex vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938926     DOI: 10.1021/pr030003l

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  45 in total

1.  MALDI mass spectrometric imaging of cardiac tissue following myocardial infarction in a rat coronary artery ligation model.

Authors:  Robert F Menger; Whitney L Stutts; Dhanalakshmi S Anbukumar; John A Bowden; David A Ford; Richard A Yost
Journal:  Anal Chem       Date:  2011-12-22       Impact factor: 6.986

2.  SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease.

Authors:  B C Tooker; R P Bowler; J M Orcutt; L A Maier; H M Christensen; L S Newman
Journal:  Occup Environ Med       Date:  2011-01-27       Impact factor: 4.402

Review 3.  Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis.

Authors:  Alberto Ortiz; Ziad A Massy; Danilo Fliser; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Carmine Zoccali
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

4.  Differential exoprotease activities confer tumor-specific serum peptidome patterns.

Authors:  Josep Villanueva; David R Shaffer; John Philip; Carlos A Chaparro; Hediye Erdjument-Bromage; Adam B Olshen; Martin Fleisher; Hans Lilja; Edi Brogi; Jeff Boyd; Marta Sanchez-Carbayo; Eric C Holland; Carlos Cordon-Cardo; Howard I Scher; Paul Tempst
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

5.  Clinical proteomics: present and future prospects.

Authors:  Nicole M Verrills
Journal:  Clin Biochem Rev       Date:  2006-05

6.  Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.

Authors:  Pinar B Yildiz; Yu Shyr; Jamshedur S M Rahman; Noel R Wardwell; Lisa J Zimmerman; Bashar Shakhtour; William H Gray; Shuo Chen; Ming Li; Heinrich Roder; Daniel C Liebler; William L Bigbee; Jill M Siegfried; Joel L Weissfeld; Adriana L Gonzalez; Mathew Ninan; David H Johnson; David P Carbone; Richard M Caprioli; Pierre P Massion
Journal:  J Thorac Oncol       Date:  2007-10       Impact factor: 15.609

Review 7.  Mass spectrometry-based proteomic profiling of lung cancer.

Authors:  Sebahat Ocak; Pierre Chaurand; Pierre P Massion
Journal:  Proc Am Thorac Soc       Date:  2009-04-15

8.  Affinity enrichment for mass spectrometry: improving the yield of low abundance biomarkers.

Authors:  Brianna Kim; Robyn Araujo; Marissa Howard; Ruben Magni; Lance A Liotta; Alessandra Luchini
Journal:  Expert Rev Proteomics       Date:  2018-03-22       Impact factor: 3.940

9.  Evaluating the effects of preanalytical variables on the stability of the human plasma proteome.

Authors:  Maria E Hassis; Richard K Niles; Miles N Braten; Matthew E Albertolle; H Ewa Witkowska; Carl A Hubel; Susan J Fisher; Katherine E Williams
Journal:  Anal Biochem       Date:  2015-03-10       Impact factor: 3.365

Review 10.  Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears.

Authors:  M E de Noo; R A E M Tollenaar; A M Deelder; L H Bouwman
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.